You are here

Home » Reports

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 302 results
 
  • Record 1 TO 302

  1. Targeted Prodrug Therapy of Liver Cancers

    SBC: ACCLAIM BIOTECHNOLOGY            Topic: N/A

    DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) and colorectal cancer (CRC) are among the most common and deadly malignancy worldwide. CRC is the second leading cause of cancer-related death in the USA, mostly due to metastases to the

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  2. A2A Adenosine Receptor Agonist for the Treatment of IBD

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents on the formulation and use of a family of potent and highly selective agonists of A2A adenosin

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  3. Rare Cell Isolation for Morphological & Molecular Study

    SBC: Adeptas, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): A first step in the elucidation of the genetic changes and molecular profiles associated with the development of cancer is the isolation of rare tumor cells from a background of millions of normal cells, or the fracti

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  4. Lossless ROI Watermarking of Medical Images

    SBC: Advanced Digital Imaging Research, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this project is to develop innovative lossless regions-of-interest (ROI) watermarking techniques to make the usage, archiving, and communication of medical images much more secure and manageable. Currently

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  5. OTF Transistor Microarray for Cancer Diagnosis

    SBC: AGAVE BIOSYSTEMS INC.            Topic: N/A

    DESCRIPTION (provided by applicant): In response to the solicitation for development of nanotechnologies to improve cancer diagnosis by NCI, Agave BioSystems, in collaboration with Dr. George Malliaras, of the Department of Materials Science and Engine

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  6. Combinatorial Molecular Array Analysis via MEF/MALDI/MS

    SBC: AGAVE BIOSYSTEMS INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Despite numerous advances in high throughput screening (HTS) and system automation, the identification of specific ligands remains time consuming and resource intensive. A major obstacle to more efficient screening

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  7. Recombinant human lactoferrin to treat oral mucositis

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION: Oral mucositis is a major dose-limiting toxic effect of intensive cancer chemotherapy and radiotherapy. In addition to the morbidity directly caused by severe oral mucositis, it can cause secondary morbidities by limiting oral intake or e

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  8. Lactoferrin in Primate and Mouse Models of Asthma

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this research is to extend work to determine the efficacy of orally administered recombinant human lactoferrin (rhLF) in an established primate model of asthma. Asthma is one of the most prevalent chr

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  9. MicroRNA Expression Profiling

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): MicroRNAs are small, 19-25mer RNAs that are encoded in the genomes of upper eukaryotes. MicroRNAs appear to regulate global gene expression by modulating the translation of mRNAs transcribed from key genes. Although th

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  10. Cost-Effective Manufacturing of Human Quality mRNA

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall objective of this proposal is to develop methods for the cost-effective, large-scale synthesis (up to kilograms amounts) of capped RNA. Companies such as Wyeth Vaccines, AlphaVax and Merix Biosciences are u

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government